Boehringer Ingelheim implements additional guidance supporting appropriate use of Pradaxa® (dabigatran etexilate) in Europe
27 October 2011 | By Boehringer Ingelheim
Update across Europe on Pradaxa®...
List view / Grid view
27 October 2011 | By Boehringer Ingelheim
Update across Europe on Pradaxa®...
26 October 2011 | By Biogen Idec
Positive top-line results announced...
26 October 2011 | By Bristol-Myers Squibb Company
Licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination...
26 October 2011 | By GlaxoSmithKline
GSK has joined WIPO Re:Search...
26 October 2011 | By AstraZeneca
US FDA has extended the action date for dapagliflozin for the treatment of type 2 diabetes by three months...
25 October 2011 | By kdm communications
Tecan’s PMP™ option for Freedom EVO® workstations provides Swiss BioQuant with real-time quality control...
24 October 2011 | By H. Lundbeck A/S
The FDA has approved Onfi™ (clobazam)...
24 October 2011 | By Gilead Sciences Inc
Gilead & GlobeImmune enter into an exclusive worldwide license & collaboration agreement...
24 October 2011 | By Abbott
New test based on FISH technology detects chromosomal abnormality to help predict prognosis of patients with AML...
24 October 2011 | By Novartis
Positive results from three Phase II trials...
24 October 2011 | By Sanofi
Sanofi announced the appointment of David Meeker as Chief Executive Officer of Genzyme, effective November 1, 2011...
24 October 2011 | By Merck
Merck announced results from two 26-week investigational Phase III clinical studies...
22 October 2011 | By Biogen Idec
Biogen Idec and Abbott announced additional results from the SELECT Phase 2b trial...
22 October 2011 | By Sanofi
New results from the CARE-MS I trial...
21 October 2011 | By Janssen Pharmaceuticals Inc.
New HIV data to be presented at EACS 2011...